Skip to main content
. 2011 Mar;178(3):1395–1402. doi: 10.1016/j.ajpath.2010.12.011

Figure 2.

Figure 2

Growth advantage by mutant IDH1 in BRAF-mutated melanoma cells. A: Immunoblot analysis of mock, wild-type IDH1 (WT1 and 2), and mutant IDH1 (MUT1 and 2). The FLAG-tagged wild or mutant (R132H) IDH1 genes were introduced in BRAF-mutated G361 cells. The cell lysates were electrophoresed and immunoblotted with anti-flag antibody. Asterisk indicates nonspecific signal. B: In vitro cell proliferation of mock, wild-type (WT1 and 2), and mutant (MUT1 and 2) IDH1-expressing clones under two culture conditions (DMEM supplemented with 10% or with 1% serum). C: Colony-forming activity of mock, wild-type IDH1 (WT1 and 2), and mutant IDH1 (MUT1 and 2). Representative plate of each clone is shown at the bottom. D: Migration activity of mock, wild-type IDH1 (WT1 and 2) and mutant IDH1 (MUT1 and 2). Representative picture of migrated cells in each clone is shown at the bottom. E: The weight of in vivo tumors produced by mock, wild-type (WT1), and mutant (MUT1) IDH1-expressing clones (Mock: n = 5, WT1: n = 5, MUT: n = 8) (left). Histological appearance (hematoxylin-eosin staining) of tumors formed by mock and mutant IDH1-expressing clones (right). Scale bar = 100 μm.